195 related articles for article (PubMed ID: 33285053)
1. Polymorphisms in TYMS for Prediction of Capecitabine-Induced Hand-Foot Syndrome in Chinese Patients with Colorectal Cancer.
Dong SQ; Wang TM; Zhang JB; He YQ; Xue WQ; Wu ZY; Yang DW; Cao LJ; Huang JW; Li XZ; Zhang PF; Zheng XH; Jia WH
Cancer Res Treat; 2021 Jul; 53(3):724-732. PubMed ID: 33285053
[TBL] [Abstract][Full Text] [Related]
2. Evaluating the role of ENOSF1 and TYMS variants as predictors in fluoropyrimidine-related toxicities: An IPD meta-analysis.
Hamzic S; Kummer D; Froehlich TK; Joerger M; Aebi S; Palles C; Thomlinson I; Meulendijks D; Schellens JHM; García-González X; López-Fernández LA; Amstutz U; Largiadèr CR
Pharmacol Res; 2020 Feb; 152():104594. PubMed ID: 31838077
[TBL] [Abstract][Full Text] [Related]
3. A candidate gene study of capecitabine-related toxicity in colorectal cancer identifies new toxicity variants at DPYD and a putative role for ENOSF1 rather than TYMS.
Rosmarin D; Palles C; Pagnamenta A; Kaur K; Pita G; Martin M; Domingo E; Jones A; Howarth K; Freeman-Mills L; Johnstone E; Wang H; Love S; Scudder C; Julier P; Fernández-Rozadilla C; Ruiz-Ponte C; Carracedo A; Castellvi-Bel S; Castells A; Gonzalez-Neira A; Taylor J; Kerr R; Kerr D; Tomlinson I
Gut; 2015 Jan; 64(1):111-20. PubMed ID: 24647007
[TBL] [Abstract][Full Text] [Related]
4. Polymorphisms of MTHFR and TYMS predict capecitabine-induced hand-foot syndrome in patients with metastatic breast cancer.
Lin S; Yue J; Guan X; Yuan P; Wang J; Luo Y; Fan Y; Cai R; Li Q; Chen S; Zhang P; Li Q; Ma F; Xu B
Cancer Commun (Lond); 2019 Oct; 39(1):57. PubMed ID: 31601265
[TBL] [Abstract][Full Text] [Related]
5. Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy.
Lecomte T; Ferraz JM; Zinzindohoué F; Loriot MA; Tregouet DA; Landi B; Berger A; Cugnenc PH; Jian R; Beaune P; Laurent-Puig P
Clin Cancer Res; 2004 Sep; 10(17):5880-8. PubMed ID: 15355920
[TBL] [Abstract][Full Text] [Related]
6. Predictors of Hand-Foot Syndrome and Pyridoxine for Prevention of Capecitabine-Induced Hand-Foot Syndrome: A Randomized Clinical Trial.
Yap YS; Kwok LL; Syn N; Chay WY; Chia JWK; Tham CK; Wong NS; Lo SK; Dent RA; Tan S; Mok ZY; Koh KX; Toh HC; Koo WH; Loh M; Ng RCH; Choo SP; Soong RCT
JAMA Oncol; 2017 Nov; 3(11):1538-1545. PubMed ID: 28715540
[TBL] [Abstract][Full Text] [Related]
7. Capecitabine-induced cerebellar toxicity and TYMS pharmacogenetics.
Saif MW
Anticancer Drugs; 2019 Apr; 30(4):431-434. PubMed ID: 30875351
[TBL] [Abstract][Full Text] [Related]
8. Integrating
Ntavatzikos A; Spathis A; Patapis P; Machairas N; Peros G; Konstantoudakis S; Leventakou D; Panayiotides IG; Karakitsos P; Koumarianou A
World J Gastroenterol; 2017 Aug; 23(32):5913-5924. PubMed ID: 28932083
[TBL] [Abstract][Full Text] [Related]
9. Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms and toxicity to capecitabine in advanced colorectal cancer patients.
Sharma R; Hoskins JM; Rivory LP; Zucknick M; London R; Liddle C; Clarke SJ
Clin Cancer Res; 2008 Feb; 14(3):817-25. PubMed ID: 18245544
[TBL] [Abstract][Full Text] [Related]
10. Gender-dependent association of
Ioannou C; Ragia G; Balgkouranidou I; Xenidis N; Amarantidis K; Koukaki T; Biziota E; Kakolyris S; Manolopoulos VG
Pharmacogenomics; 2021 Jul; 22(11):669-680. PubMed ID: 34100299
[No Abstract] [Full Text] [Related]
11. Toxicity and efficacy of 5-fluorouracil and capecitabine in a patient with TYMS gene polymorphism: A challenge or a dilemma?
Shahrokni A; Rajebi MR; Saif MW
Clin Colorectal Cancer; 2009 Oct; 8(4):231-4. PubMed ID: 19822515
[TBL] [Abstract][Full Text] [Related]
12. SNPs in the COX-2/PGES/EP signaling pathway are associated with risk of severe capecitabine-induced hand-foot syndrome.
Liao X; Huang L; Yu Q; He S; Li Q; Huang C; Yuan X
Cancer Chemother Pharmacol; 2020 Apr; 85(4):785-792. PubMed ID: 32193619
[TBL] [Abstract][Full Text] [Related]
13. Thymidylate synthase (TYMS) and dihydropyrimidine dehydrogenase (DPYD) polymorphisms in the Korean population for prediction of 5-fluorouracil-associated toxicity.
Cho HJ; Park YS; Kang WK; Kim JW; Lee SY
Ther Drug Monit; 2007 Apr; 29(2):190-6. PubMed ID: 17417073
[TBL] [Abstract][Full Text] [Related]
14. A polymorphism in the cytidine deaminase promoter predicts severe capecitabine-induced hand-foot syndrome.
Caronia D; Martin M; Sastre J; de la Torre J; García-Sáenz JA; Alonso MR; Moreno LT; Pita G; Díaz-Rubio E; Benítez J; González-Neira A
Clin Cancer Res; 2011 Apr; 17(7):2006-13. PubMed ID: 21325291
[TBL] [Abstract][Full Text] [Related]
15. Germline TYMS genotype is highly predictive in patients with metastatic gastrointestinal malignancies receiving capecitabine-based chemotherapy.
Joerger M; Huitema AD; Boot H; Cats A; Doodeman VD; Smits PH; Vainchtein L; Rosing H; Meijerman I; Zueger M; Meulendijks D; Cerny TD; Beijnen JH; Schellens JH
Cancer Chemother Pharmacol; 2015 Apr; 75(4):763-72. PubMed ID: 25677447
[TBL] [Abstract][Full Text] [Related]
16. Possible Pathways of Capecitabine-Induced Hand-Foot Syndrome.
Lou Y; Wang Q; Zheng J; Hu H; Liu L; Hong D; Zeng S
Chem Res Toxicol; 2016 Oct; 29(10):1591-1601. PubMed ID: 27631426
[TBL] [Abstract][Full Text] [Related]
17. Identification of new SNPs associated with severe toxicity to capecitabine.
Pellicer M; García-González X; García MI; Robles L; Grávalos C; García-Alfonso P; Pachón V; Longo F; Martínez V; Blanco C; Iglesias I; Sanjurjo M; López-Fernández LA
Pharmacol Res; 2017 Jun; 120():133-137. PubMed ID: 28347776
[TBL] [Abstract][Full Text] [Related]
18. TYMS Gene Polymorphisms in Breast Cancer Patients Receiving 5-Fluorouracil-Based Chemotherapy.
Chao YL; Anders CK
Clin Breast Cancer; 2018 Jun; 18(3):e301-e304. PubMed ID: 28899623
[No Abstract] [Full Text] [Related]
19. Regulatory CDH4 Genetic Variants Associate With Risk to Develop Capecitabine-Induced Hand-Foot Syndrome.
Ruiz-Pinto S; Pita G; Martín M; Nuñez-Torres R; Cuadrado A; Shahbazi MN; Caronia D; Kojic A; Moreno LT; de la Torre-Montero JC; Lozano M; López-Fernández LA; Ribelles N; García-Saenz JA; Alba E; Milne RL; Losada A; Pérez-Moreno M; Benítez J; González-Neira A
Clin Pharmacol Ther; 2021 Feb; 109(2):462-470. PubMed ID: 32757270
[TBL] [Abstract][Full Text] [Related]
20. Variants in CDA and ABCB1 are predictors of capecitabine-related adverse reactions in colorectal cancer.
García-González X; Cortejoso L; García MI; García-Alfonso P; Robles L; Grávalos C; González-Haba E; Marta P; Sanjurjo M; López-Fernández LA
Oncotarget; 2015 Mar; 6(8):6422-30. PubMed ID: 25691056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
